Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma

被引：1

作者：

Peng, Fengping ^{[1
]}

Wang, Yuan ^{[2
,3
]}

Zhao, Jiliang ^{[2
,3
]}

Liu, Hui ^{[1
]}

Liu, Zhaoyun ^{[1
]}

Ding, Kai ^{[1
]}

Zhang, Hongkai ^{[2
,3
]}

Fu, Rong ^{[1
]}

机构：

[1] Tianjin Med Univ, Dept Hematol, Gen Hosp, Tianjin, Peoples R China

[2] Nankai Univ, State Key Lab Med Chem Biol, Tianjin, Peoples R China

[3] Nankai Univ, Coll Life Sci, Tianjin, Peoples R China

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷 / 03期

基金：

中国国家自然科学基金;

关键词：

B-cell maturation antigen; bispecific T-cell engager; gene therapy; in vivo electroporation; multiple myeloma;

D O I：

10.1111/bjh.18230

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The delivery of bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA) and CD3 using the gene therapy approach is a promising alternative for BsAb administration in patients with multiple myeloma (MM). In the present study, we evaluated the efficacy of this approach using a xenograft model. Tumour growth was significantly delayed in mice treated with single electroporation-enhanced intramuscular injection of plasmid DNA encoding BCMA/CD3 BsAb in contrast to the vehicle control-treated group. Limited toxicity was observed following treatment. This study demonstrates that the gene therapy-based approach for the delivery of BCMA/CD3 BsAb is effective and safe for the treatment of MM.

引用

页码：417 / 421

页数：5

共 50 条

[1] Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
Krishnan, Amrita Y.
Garfall, Alfred L.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Nahi, Hareth
San-Miguel, Jesus F.
Oriol, Albert
Rosinol, Laura
Chari, Ajai
Bhutani, Manisha
Karlin, Lionel
Benboubker, Lotfi
Pei, Lixia
Verona, Raluca
Girgis, Suzette
Stephenson, Tara
Goldberg, Jenna D.
Banerjee, Arnob
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Garfall, Alfred L.
Usmani, Saad Z.
Mateos, Maria-Victoria
Nahi, Hareth
van de Donk, Niels W. C. J.
San-Miguel, Jesus F.
Rocafiguera, Albert Oriol
Rosinol, Laura
Chari, Ajai
Bhutani, Manisha
Pei, Lixia
Verona, Raluca
Girgis, Suzette
Stephenson, Tara
Goldberg, Jenna D.
Banerjee, Arnob
Krishnan, Amrita
BLOOD, 2020, 136
[3] Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).
Bahlis, Nizar J.
Raje, Noopur S.
Costello, Caitlin
Dholaria, Bhagirathbhai R.
Solh, Melhem M.
Levy, Moshe Y.
Tomasson, Michael H.
Dube, Harman
Liu, Feng
Liao, Kai Hsin
Basu, Cynthia
Skoura, Athanasia
Chan, Edward Michael
Trudel, Suzanne
Jakubowiak, Andrzej J.
Chu, Michael P.
Gasparetto, Cristina
Dalovisio, Andrew
Sebag, Michael
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] An Anti-B Cell Maturation Antigen Bispecific Antibody for Multiple Myeloma
Ramadoss, Nitya S.
Schulman, Andrew D.
Choi, Sei-hyun
Rodgers, David T.
Kazane, Stephanie A.
Kim, Chan Hyuk
Lawson, Brian R.
Young, Travis S.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2015, 137 (16) : 5288 - 5291
[5] Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).
Usmani, Saad Zafar
Mateos, Maria-Victoria
Nahi, Hareth
Krishnan, Amrita Y.
van de Donk, Niels W. C. J.
San Miguel, Jesus
Oriol, Albert
Rosinol, Laura
Chari, Ajai
Adams, Homer
Girgis, Suzette
Lin, Shun Xin Wang
Stephenson, Tara
Kemmerer, Kristy
Smit, Jennifer
Elsayed, Yusri A.
Infante, Jeffrey R.
Goldberg, Jenna D.
Banerjee, Arnob
Garfall, Alfred L.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[6] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
Cortes-Selva, Diana
Casneuf, Tineke
Vishwamitra, Deeksha
Stein, Sarah
Perova, Tatiana
Skerget, Sheri
Ramos, Elena
van Steenbergen, Laure
De Maeyer, Dries
Boominathan, Rengasamy
Lau, Onsay
Davis, Cuc
Banerjee, Arnob
Stephenson, Tara
Uhlar, Clarissa M.
Kobos, Rachel
Goldberg, Jenna D.
Pei, Lixia
Trancucci, Danielle
Girgis, Suzette
Lin, Shun Xin Wang
Wu, Liviawati S.
Moreau, Philippe
Usmani, Saad
Bahlis, Nizar Jacques
Van de Donk, Niels W. C. J.
Verona, Raluca
BLOOD, 2022, 140
[7] Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
Pillarisetti, Kodandaram
Powers, Gordon
Luistro, Leopoldo
Babich, Alexander
Baldwin, Eric
Li, Yingzhe
Zhang, Xiaochun
Mendonca, Mark
Majewski, Nate
Nanjunda, Rupesh
Chin, Diana
Packman, Kathryn
Elsayed, Yusri
Attar, Ricardo
Gaudet, Francois
BLOOD ADVANCES, 2020, 4 (18) : 4538 - 4549
[8] Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Polepally, Akshanth R.
Biesdorf, Carla
Uddin, Muhammad Erfan
Boehm, Nils
Ross, Jeremy A.
Kumar, Shaji Kunnathu
Voorhees, Peter M.
D'Souza, Anita
Weisel, Katja
Bueno, Orlando
Talati, Chetasi
Menon, Rajeev M.
BLOOD, 2023, 142
[9] Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Moreau, Philippe
Usmani, Saad Z.
Garfall, Alfred L.
van de Donk, Niels W. C. J.
Nahi, Hareth
San-Miguel, Jesus
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas
Rosino, Laura
Chari, Ajai
Karlin, Lionel
Benboubker, Lotfi
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martínez-López, Joaquín
Sidana, Surbhi
Pei, Lixia
Trancucci, Danielle
Verona, Raluca I.
Girgis, Suzette
Olyslager, Yunsi
Jaffe, Mindy
Uhlar, Clarissa M.
Stephenson, Tara
Van Rampelbergh, Rian
Banerjee, Arnob
Goldberg, Jenna D.
Kobos, Rachel
Krishnan, Amrita Y.
BLOOD, 2021, 138
[10] A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
Sun, Mingyuan
Qi, Junyuan
Qiu, Lugui
Jin, Jie
Li, Xin
Wei, Yongqiang
Zhang, Guimin
Liu, Xue
Yin, Shaohong
BLOOD, 2023, 142

← 1 2 3 4 5 →